Urovant’s Vibegron Fails to Meet its Primary Endpoint in P-IIa Study for IBS Pain

November 26, 2020 Auto Bot Clinical Trials, irritable bowel syndrome, reports, results, Study, Treatment 0

Shots:

  • The P-IIa study involves assessing vibegron (75mg,qd) in 222 women with abdominal pain due to IBS with IBS-D (diarrhea) and IBS-M (mixed IBS) across 35 sites in the US
  • The study did not meet its 1EPs i.e. at least a 30 percent improvement in average worst abdominal pain @12wks. ( 40.9% vs 42.9%), well tolerated and did not lead to worsening of IBS symptoms
  • Vibegron is (PO,qd) is a beta-3 agonist that is being evaluated for OAB, OAB+BPH in men & for abdominal pain associated with IBS

Click here ­to­ read full press release/ article | Ref: Businesswire | Image: Urovant

The post Urovant’s Vibegron Fails to Meet its Primary Endpoint in P-IIa Study for IBS Pain first appeared on PharmaShots.